Targeted therapy in chronic myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 8, Issue 1, 2008, Pages 99-110

  Jabbour, Elias ^a   Cortes, Jorge E ^a   Ghanem, Hady ^a   O'Brien, Susan ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Dasatinib; Imatinib; Nitotinib

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; AT 9283; BCR ABL PROTEIN; BOSUTINIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; HARRINGTONINE; IMATINIB; INTERFERON; KW 2449; LONAFARNIB; NILOTINIB; PHA 739358; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; EDEMA; GENE MUTATION; HUMAN; HYPERGLYCEMIA; LEUKEMOGENESIS; MOLECULAR DYNAMICS; MONOTHERAPY; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PHARMACOLOGICAL BLOCKING; PLEURA EFFUSION; PRIMARY HEALTH CARE; PROGNOSIS; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MYELOID LEUKEMIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE;

EID: 38349016567     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.1.99     Document Type: Review

References (92)

1. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin. Hematol. 44, 4-14 (2007).
2. Hehlmann R, Berger U, Pfirrmann M et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 109, 4686-4692 (2007).
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 (2000).
4. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med. 145, 913-923 (2006).
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082 (1990).
6. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
7. Meyn MA III, Wilson MB, Abdi FA et al. Src family kinases phosphorylate the Bcr-Abl-SH3-SH2 region and modulate Bcr-Abl transforming activity. J. Biol. Chem. 281, 30907-30916 (2006).
8. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem. 275, 18581-18585 (2000).
9. Klejman A, Schreiner SJ, Nieborowska-Skorska M et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 21, 5766-5774 (2002).
10. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21, 8075-8088 (2002).
11. Mughal TI, Goldman JM. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Front Biosci. 11, 198-208 (2006).
12. Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 16, 1402-1411 (2002).
13. Calabretta B, Perrorti D. The biology of CML blast crisis. Blood 103, 4010-4022 (2004).
14. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
15. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
16. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
17. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood 99, 1928-1937 (2002).
18. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood 99, 3530-3539 (2002).
19. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101, 473-475 (2003).
20. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 102, 2702-2703 (2003).
21. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin. Cancer Res. 9, 2092-2017 (2003).
22. Kantatjian H, Talpaz M, O'Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 63, 2873-2878 (2004).
23. Aoki E, Kantarjian H, O'Brien S et al. High-dose imatinib mesylate treatment in patients with untreated early chronic phase chronic myeloid leukemia: 2.5-year follow-up. J. Clin. Oncol. 24(Suppl.), S345 (2006) (Abstract 6535).
24. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin. Hematol. 44, 15-24 (2007).
25. Litzow MR. Imatinib resistance: obstacles and opportunities. Arch. Pathol. Lab. Med. 130, 669-679 (2006).
26. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood 110, 2242-2249 (2007).
27. Soverini S, Colarossi S, Gnani A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12, 7374-7379 (2006).
28. Jabbour E, Kantarjian H, Jones D et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic mycloid leukemia treated with imatinib mesylate. Leukemia 20, 1767-1773 (2006).
29. Lahaye T, Riehin B, Berger U et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103, 1659-1669 (2005).
30. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia 16, 2190-2196 (2002).
31. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653 (2005).
32. Nicolini FE, Corm S, Le QH et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French Intergroup of CML (Fi(varphi)-LMC GROUP). Leukemia 20, 1061-1066 (2006).
33. Cortes J, Jabbour E, Kantarjian H et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12), 4005-4011 (2007).
34. Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to ST1571. Blood 101, 690-698 (2003).
35. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 279, 34227-34239 (2004).
36. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104, 3739-3745 (2004).
37. Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496-3499 (2007).
38. Wendel FIG, de Stanchina E, Cepero E et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc. Natl Acad. Sci. USA 103, 7444-7449 (2006).
39. O'Hare,T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN 107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505 (2005).
40. Lombardo LJ, Lee FY; Chen P et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor wiih potent antitumor activity in preclinical assays. J. Med Chem. 47, 6658-6661 (2004).
41. Lee FY, Wen ML, Bhide R et al. Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 106 (2005) (Abstract 1994).
42. Tokarski JS, Newitt JA, Chang CY et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790-5797 (2006).
43. Shah NP, Tran C, Lee FY et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
44. Bradeen HA, Eide CA, O'Hare T et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332-2338 (2006).
45. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl J. Med. 354, 2531-2541 (2006).
46. Guilhot F, Apperley J, Facon T et al. Dasatinib induces durable cytogenetic responses in patients with chronic-phase CML with resistance or intolerance to imatinib: updated results of the CA180013 (START-C) trial. Haematologica 92(S1), 128 (2007) (Abstract 0358).
47. Cortes J, Kim DW, Guithot F et al. Dasatinib (SPRYCEL) in patients with chronic myelogenous leukemia in accelerated phase that is imatinib-resistant or -intolerant: updated results of the CA180-005 START-A Phase II study. Blood (ASH Annual Meeting Abstracts) 108, (2006) (Abstract 2160).
48. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109, 3207-3213 (2007).
49. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood 109, 5143-5150 (2007).
50. Müller MC, Branford S, Radich J et al. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. Haematologica 92(S1), 127 (2007) (Abstract 0356).
51. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303-2309 (2007).
52. Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143-4150 (2007).
53. Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92, 401-404 (2007).
54. Hochhaus A, Kim DW, Rousselot P et al. Dasatinib dose and schedule optimization in chronic-phdse CML resistant or intolerant to imatinib: results from a randomized Phase-III trial (CA180034). Haematologica 92(S1), 128-129 (2007) (Abstract 0359).
55. Dombret H, Ottmann OG, Goli Y et al. Dasatinib 40 mg QD vs 70 mg bid in advanced-phase CML or Ph ALL resistant or intolerant to imatinib: results from a randomized, Phase-III trial (CA180035). Haematologica 92(S1), 319 (2007) (Abstract 0859).
56. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005).
57. Golemovic M, Verstovsek S, Giles F et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 11, 4941-4947 (2005).
58. Weisberg E, Manley P, Mestan J et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94, 1765-1769 (2006).
59. von Bubnoff N, Manley PW, Mestan J et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108, 1328-1333 (2006).
60. Ray A, Cowan-Jacob SW, Manley PW, Mestin J, Griffin JD. Identification of ACR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109, 5011-5015 (2007).
61. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551 (2006).
62. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540-3546 (2007).
63. le Coutre P, Larson R, Kantarjian H et al. A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase. Haematologica 92(S1), 207-208 (2007) (Abstract 0557).
64. + acute lymphoblastic leukemia. Haematologica 92(S1), 207 (2007) (Abstract 0556).
65. Soverini S, Saglio G, Branford S et al. In patients with chronic myelogenous leukemia, response dynamics to nilotinib after imatinib failure depend on the type of BCR-ABL mutations. Haematologica 92(S1), 320 (2007) (Abstract 0861).
66. Breccia M, Muscaritoli M, Gentilini F et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk. Res. 31(12), 1770-1772 (2007).
67. Golas JM, Arndt K, Etienne C et al. SKI-606, a4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63, 375-381 (2003).
68. + neoplastic cells. Cancer Res. 66, 11314-11322 (2006).
69. Brummendorf T, Cortes J, Kantarjian H et al. Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. Haematologica 92(S1), 116 (2007) (Abstract 0321).
70. Kimura S, Naito H, Segawa H et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106, 3948-3954 (2005).
71. Craig AR, Kantarjian HM, Cortes JE et al. A Phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML) or arute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J. Clin. Oncol. (ASCO Annual Meeting Proceedings) 25(18S), 368S (2007) (Abstract 7046).
72. Giles FJ, Cortes J, Jones D et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T3151 BCR-ABL mutation. Blood 109, 500-502 (2007).
73. Giles J, Cortes J, Bergstrom DA et al. MK-0457, a novel multikinase inhibitor, is active in patients with chronic myeloid leukemia and acute lymphocytic leukemia with the T3151 BCR-ABL resistance mutation and patients with refractory JAK-2 positive myeloproliferative diseases. Haematologica 92(S1), 347 (2007) (Abstract 0927).
74. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat. Rev. Drug Discov. 5, 717-718 (2006).
75. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7, 345-356 (2007).
76. Cortes J, Albitar M, Thomas D et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101, 1692-1697 (2003).
77. Borthakur G, Kantarjian H, Daley G et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106, 346-352 (2006).
78. Issa JP, Gharibyan V, Cortes J et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23, 3948-3956 (2005).
79. Quintas-Cardama A, Kantarjian H, Garcia-Manero G et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109, 248-255 (2007).
80. Copland M, Hamilton A, Elrick LJ et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532-4539 (2006).
81. Quintas-Cardama A, Kantarjian H, O'Brien S et al. Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase. Haematologica 92(S1), 129 (2007) (Abstract 0360).
82. Jabbour E, Cortes J, Giles F et al. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia. Blood (ASH Annual Meeting Abstracts) 108 (2006) (Abstract 2172).
83. Giles F, le Coutre R Bhalla K et al. Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or intolerant chronic phase and accelerated phase Philadelphia-positive chronic myelogenous leukemia. Haematologica 92(S1), 206-207 (2007) (Abstract 0554).
84. Quintas-Cardama A, Kantarjian H, Jones D et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109, 497-499 (2007).
85. O'Hare, T, Walters DK, Stoffregen EP et al. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/ Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 11, 6987-6993 (2005).
86. + leukemias. Blood 109, 2112-2120 (2007).
87. Cortes J, Jabbour E, Daley GQ et al. Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients with chronic myeloid leukemia after failure to imatinib. Cancer 110, 1295-1302 (2004) (Abstract 1009).
88. Cortes J, Garcia-Manero G, O'Brien S et al. A Phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients with chronic myeloid leukemia in chronic phase who failed IM therapy. Blood (ASH Annual Meeting Abstracts) 104, (2004) (Abstract 1011).
89. Marin D, Kaeda JS, Andreasson C et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103, 1850-1855 (2005).
90. La Rosee P, O'Dwyer ME, Druker BJ. Insights hom pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16, 1213-1219 (2002).
91. Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657-662 (2005).
92. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood 108, 1809-1820 (2006).